Image

Sequencing in Inflammatory Bowel Diseases (IBD) Therapy: "the Latium Net".

Sequencing in Inflammatory Bowel Diseases (IBD) Therapy: "the Latium Net".

Recruiting
18-70 years
All
Phase N/A

Powered by AI

Overview

Patients with IBD, both UC and CD, who fulfil the inclusion and exclusion criteria will be included consecutively:

  • Retrospective cohort Patients treated with IBD from January 2015 to June 2024 will be included.
  • Prospective cohort Consecutive patients with IBD who are starting, from clinical practice, new biological/small molecule therapies, failure (already exposed) to a mechanism of action (for anti TNF-alpha, more than one molecule is allowed), and who belong to the Lazio Regional Health System.

Eligible subjects will be identified among patients belonging to the IBD Unit of the Digestive Diseases Centre (CEMAD) of the Foundation and to all the other IBD Units of all the centres specified in Annex 1. Based on the number of patients referred to the clinics, we estimate 112 patients per month, the time for recruitment is 24 months.

Potential study participants will receive oral and written information about the study. Patients who agree to participate in the study will be asked to sign a written informed consent according to GCP.

Description

Multicenter, ambispectic observational study with drug

Eligibility

Inclusion Criteria:

  1. Age 18 to 70 years
  2. Patients with a previous diagnosis of CD or UC at least 3 months before baseline.
  3. Patients who have already failed at least one advanced (biological or small molecule) therapy for IBD and who have experienced failure to at least one mechanism of action (failure is defined as primary failure, secondary failure, or intolerance).
  4. Patients who have already started a new advanced therapy for IBD based on clinical practice indication (primary loss of response, secondary loss of response, intolerance to the previous drug) since at least 1 week and up to 8 weeks after starting it.
  5. Written informed consent certifying the willingness of the subject to participate to the study.

Exclusion Criteria:

  1. Age < 18 years.
  2. Patients with diagnosis of indeterminate colitis.
  3. Patients naive to advanced (biological or small molecule) therapy for IBD.
  4. Refusal to sign written informed consent certifying the willingness of the subject to participate to the study.

Study details
    IBD (Inflammatory Bowel Disease)

NCT06603337

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.